Predictive Oncology Inc

Predictive Oncology, Inc. engages in the application of artificial intelligence medicine business and provision of cleared STREAMWAY System for automated, direct-to-drain medical fluid disposal and associated products. It operates through the following segments: Helomics, zPREDICTA, Skyline, Soluble, and Corporate. The Helomics segment includes clinical testing and contract research services that include the application of AI. The zPREDICTA segment specializes in organ-specific disease models that provide 3D reconstruction of human tissues accurately representing each disease state and mimicking drug response enabling accurate testing of anticancer agents. The Skyline segment is composed of the STREAMWAY System product sales, and its TumorGenesis subsidiary is included within corporate. The Soluble segment provides services using an automated system that conducts self-interaction chromatography screens, using additives and excipients commonly included in protein formulations resulting in soluble and physically stable formulations for biologics. The company was founded by Lawrence W. Gadbaw, Peter L. Morawetz, and Jeffrey K. Drogue on April 23, 2002 and is headquartered in Eagan, MN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Predictive Oncology Inc advances in cancer research and cost optimization

POAI's Q2 2024 performance reflects progress in research, technology, and cost optimization strategies.
While facing challenges in financial metrics, the company's focus on innovation and shareholder value creation positions it for long-term success.
Opportunities lie in leveraging AI capabilities, strategic partnerships, and revenue growth initiatives to drive future growth and sustainability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Predictive Oncology, Inc. engages in the application of artificial intelligence medicine business and provision of cleared STREAMWAY System for automated, direct-to-drain medical fluid disposal, and associated products. It operates through the following segments: Helomics, zPREDICTA, Skyline, Soluble, and Corporate. The Helomics segment includes contract services that include the application of AI, partnering projects, and clinical testing. The zPREDICTA segment specializes in organ-specific disease models that provide 3D reconstruction of human tissues accurately representing each disease state and mimicking drug response enabling accurate testing of anticancer agents. The Skyline segment is composed of the STREAMWAY System product sales, and its TumorGenesis subsidiary is included within the Corporate segment. The Soluble segment provides services using an automated system that conducts self-interaction chromatography screens, using additives and excipients commonly included in protein formulations resulting in soluble and physically stable formulations for biologics. The company was founded by Lawrence W. Gadbaw, Peter L. Morawetz, and Jeffrey K. Drogue on April 23, 2002 and is headquartered in Pittsburgh, PA.

Increases Readiness for Commercialization with Expanded Portfolio of Solutions for Precision Medicine

Predictive Oncology Reports Second Quarter 2020 Financial Results, Provides Business Update

Adds Industry, Business Development and Financial Expertise Adds Industry, Business Development and Financial Expertise

Predictive Oncology Refreshes Board with Appointment of Three New Directors

Acquisition Focused on Accelerating Commercialization of AI-driven Drug Discovery and Development Acquisition Focused on Accelerating Commercialization of AI-driven Drug Discovery and Development

Predictive Oncology Completes Acquisition of Quantitative Medicine

MINNEAPOLIS, June  29, 2020  (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (the “Company,” “Predictive Oncology,” “we,” “our” or “us”) (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced the closing of its previously announced transaction resulting in gross cash proceeds to the Company of approximately $2.2 million, prior to deducting placement agent fees and offering expenses, through the exercise of certain existing warrants by several holders to purchase an aggregate of up to 1,396,826 shares of common stock at an exercise price of $1.575 per share. The shares of common stock issued upon exercise of the existing warrants are registered for resale pursuant to a registration statement on Form S-1 (File No. 333-239207).

Predictive Oncology Inc. Announces Receipt of Cash Proceeds of $2.2 Million from Exercise of Warrants

A Top US Medical Institution Places the First Commercial Order for the Media used to grow Ovarian Cancer Cell Types that are Exceedingly Difficult to Grow and Retain the Signatures of the Patient Derived Sample.

Predictive Oncology’s TumorGenesis Division Secures First Commercial Sale of its Novel Ovarian Cancer Cell Media

CancerQuest 2020 Study on Schedule for Completion in Q2 2020 CancerQuest 2020 Study on Schedule for Completion in Q2 2020

Predictive Oncology Reports First Quarter 2020 Financial Results, Provides Business Update

MINNEAPOLIS, June  02, 2020  (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (the “Company”) a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that it has completed the acquisition of the assets of Soluble Therapeutics, Inc. and BioDtech, Inc., each of which is a wholly-owned subsidiary of InventaBioTech, Inc. The Company acquired the assets of Soluble and BioDtech, including, certain intellectual property relating to contract research organization (“CRO”) services and technology, certain equipment useful in such services and technology and all other assets of Soluble Therapeutics and BioDtech for 125,000 shares of common stock, in addition to waiving all remaining amounts due and payable to the Company under a secured promissory note of InventaBioTech in the principal amount of $1,070,000 relating to advances made by the Company in 2017.

Predictive Oncology Completes Acquisition of Soluble Therapeutics and BioDtech

MINNEAPOLIS, May  14, 2020  (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI)  has, with the announced acquisition of Soluble Therapeutics and the subsequent partnership and licensing of a novel nanoparticle vaccine technology platform recently developed by Dr. Daniel Carter, entered the race to develop a COVID19 vaccine.  The ground-breaking vaccine technology is based on a self-assembling nanoparticle called NSP10 which follows a foundational vaccine platform developed earlier by Dr. Carter and his team, using another self-assembling protein called ferritin (1).

Predictive Oncology (NASDAQ Symbol POAI) is licensing and partnering this groundbreaking NSP10 technology in the race to develop a vaccine for development

MINNEAPOLIS, May  07, 2020  (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that it has entered into definitive agreements with several institutional and accredited investors for the issuance and sale of an aggregate of 1,396,826 shares of its common stock, at a purchase price of $1.575 per share, for gross proceeds of approximately $2.2 million in a registered direct offering priced at-the-market under Nasdaq rules. Predictive Oncology has also agreed to issue to the investors unregistered warrants to purchase up to an aggregate of 1,396,826 shares of common stock. The closing of the offering is expected to occur on or about May 8, 2020, subject to the satisfaction of customary closing conditions.

Predictive Oncology Announces $2.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

MINNEAPOLIS, May  06, 2020  (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) has, with the announced acquisition of Soluble Therapeutics, Inc. and the subsequent partnership and licensing of a novel nanoparticle vaccine platform recently developed by Dr. Daniel Carter, entered the race to develop a COVID-19 vaccine.  The groundbreaking vaccine technology being developed by Dr. Carter is based on a self-assembling nanoparticle called NSP-10 (NSP is Non Specific Protein) which follows a foundational vaccine platform developed earlier by Dr. Carter and his team, using another self-assembling protein called ferritin (1), an iron storage protein found in all living things.  The ferritin platform is currently exploited by NIH in its exploration of the universal flu vaccine which completed phase I clinical trials earlier this year and is currently recruiting for a second Phase 1 trial on a modified version of the ferritin self-assembly universal vaccine (2,3). POAI has entered into an agreement with Dr. Carter under which POAI is licensing this technology, subject to certain conditions including additional documentation.

Predictive Oncology and Dr. Daniel Carter Collaborating to Develop a Potential COVID-19 Vaccine Utilizing Novel Nanoparticle Vaccine Platform, Based on NSP-10

CEO Agrees to Exchange $2.1 Million Promissory Note for Newly Issued Equity, Demonstrating Confidence in Company’s Future CEO Agrees to Exchange $2.1 Million Promissory Note for Newly Issued Equity, Demonstrating Confidence in Company’s Future

Predictive Oncology Exchanges $2.1 Million of Debt for Equity, Streamlining Capital Structure and Simplifying Balance Sheet

NEW YORK, April  22, 2020  (GLOBE NEWSWIRE) -- via NetworkNewsAudio — Predictive Oncology (NASDAQ: POAI) today announces that Company director and CEO Dr. Carl Schwartz, in an interview with  NetworkNewsWire  (NNW), discussed the Predictive Oncology’s distinctive business model and significant changes management is making to position the Company for the future.

Predictive Oncology (NASDAQ: POAI) CEO Discusses ‘Major Asset’ in Exclusive Interview

MINNEAPOLIS, March  31, 2020  (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:  POAI ) (“POAI” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced continued progress towards by its Helomics subsidiary towards the goal of developing an AI-driven predictive model of ovarian cancer (CancerQuest 2020).

POAI Subsidiary Helomics Continues Progress Towards Goal of Developing an AI-Driven Predictive Model of Ovarian Cancer

MINNEAPOLIS, March  23, 2020  (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a data and artificial intelligence (“AI”) driven discovery services company that provides predictive models of tumor drug response to improve clinical outcomes for patients, today announced that on March 19, 2020, the Company closed on its previously announced private offering of common stock and warrants resulting in gross proceeds to the Company of $3,498,612. Pursuant to the offering, the Company sold and issued 1,650,166 shares of common stock (or common stock equivalents) and issued Series A warrants to acquire 1,650,166 shares of Common Stock at $1.88 per share, exercisable immediately and terminating five and one-half years after the date of issuance, and Series B warrants to acquire 1,650,166 shares of Common Stock at $1.88 per share, exercisable immediately and terminating two years after the date of issuance.

Predictive Oncology Inc. Announces Completion of $3.5 Million Private Placement

MINNEAPOLIS, March  16, 2020  (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a data and artificial intelligence (“AI”) driven discovery services company that provides predictive models of tumor drug response to improve clinical outcomes for patients, today announced that it has entered into a securities purchase agreement with certain accredited investors to raise $3.5 million through the issuance of up to 1,650,165 shares of common stock (or common stock equivalents) and accompanying warrants to purchase an aggregate of up to 3,300,330 shares of common stock at $2.121 per share of common stock and accompanying warrants. The warrants will be exercisable immediately at an exercise price of $1.88 per share, with one-half of the warrants to expire two years after the date of issuance, and one-half to expire five and one-half years after the date of issuance.

Predictive Oncology Inc. Announces $3.5 Million Private Placement

With More Viral Outbreaks Expected, Predictive Oncology Expands AI Platforms to Aid in Vaccine and Drug Development With More Viral Outbreaks Expected, Predictive Oncology Expands AI Platforms to Aid in Vaccine and Drug Development

Predictive Oncology Launches New AI Platform for Vaccine and Drug Development Targeting Coronaviruses and Acute Respiratory Syndromes (COVID-19, MERS, and SARS)

POAI proposed acquisition of Carnegie Mellon University spin-out Quantitative Medicine further positions the company to aid in efforts to accelerate the discovery of new anti-cancers, anti-virals, antibiotics and vaccines POAI proposed acquisition of Carnegie Mellon University spin-out Quantitative Medicine further positions the company to aid in efforts to accelerate the discovery of new anti-cancers, anti-virals, antibiotics and vaccines

Predictive Oncology Provides Acquisition Update, Stresses Importance of AI in New Anti-Cancers, Anti-Virals and Vaccines

MINNEAPOLIS, Feb.  21, 2020  (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a data and artificial intelligence (“AI”) driven discovery services company that provides predictive models of tumor drug response to improve clinical outcomes for patients, today announced that its Board of Directors has unanimously appointed Dan Handley, M.S., Ph.D., to the Board.

Predictive Oncology Inc. Appoints Dan Handley, M.S.

New Formulations Will Speed Discovery of Biomarkers and Precision Therapies

Predictive Oncology Launches Innovative Specialty Media for Growing Ovarian Tumors in the Lab

AI platform was developed at the Ray and Stephanie Lane Center for Computational Biology, which became the Computational Biology Department at Carnegie Mellon University and was successfully tested by several pharma companies AI platform was developed at the Ray and Stephanie Lane Center for Computational Biology, which became the Computational Biology Department at Carnegie Mellon University and was successfully tested by several pharma companies

Predictive Oncology Inc. Signs Letter of Intent to Acquire Quantitative Medicine (qtmed.com) and an AI Engine™ (CoRE™) that Facilitates Accelerated Drug Discovery and Development

MINNEAPOLIS, Jan.  06, 2020  (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a data and artificial intelligence (“AI”) driven discovery services company that provides predictive models of tumor drug response to improve clinical outcomes for patients, today announced that its Board of Directors has unanimously appointed Pam Prior, CPA, to the Board.

Predictive Oncology Inc. Appoints Pam Prior to Board of Directors

MINNEAPOLIS, Dec.  17, 2019  (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a data and artificial intelligence (“AI”) driven discovery services company that provides predictive models of tumor drug response to improve clinical outcomes for patients, today announced that its secured promissory note that was due December 31, 2019 has been extended. 

News for Predictive Oncology Inc Stock (POAI)